(Q33950838)

30 July 2017

1 reference

title

Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients (English)

1 reference

30 July 2017

Englund JA

1

1 reference

30 July 2017

Piedra PA

series ordinal

2

1 reference

30 July 2017

Whimbey E

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 March 1997

1 reference

American Journal of Medicine

30 July 2017

published in

1 reference

30 July 2017

volume

102

1 reference

30 July 2017

issue

3A

1 reference

30 July 2017

page(s)

61-70; discussion 75-6

1 reference

Respiratory syncytial viral infection in children with compromised immune function

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Parainfluenza Virus Respiratory Infection after Bone Marrow Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Community respiratory virus infections among hospitalized adult bone marrow transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Effect of salbutamol on respiratory mechanics in bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Nebulized albuterol in acute bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Effect of salbutamol on oxygen saturation in bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

In re ribavirin: a case of premature adjudication?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Early ribavirin treatment of respiratory syncytial viral infection in high-risk children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

An outbreak of respiratory syncytial virus in a bone marrow transplant center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Fatal Syncytial Virus Pneumonia in a Laminar Airflow Room

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory syncytial virus infection in immunocompromised adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory syncytial virus infections in adult bone marrow transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory syncytial virus pneumonia in a cardiac transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Respiratory syncytial virus pneumonia in a human immunodeficiency virus-infected man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Severe respiratory syncytial virus pneumonia in an adult renal transplant recipient: successful treatment with ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

In vivo inhibition of respiratory syncytial virus by ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Complications of measles during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

7 January 2021

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

7 January 2021

Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

7 January 2021

Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

7 January 2021

Presumed respiratory syncytial virus pneumonia in three immunocompromised adults

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

7 January 2021

Environmental exposure to ribavirin aerosol.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900014-4

7 January 2021

10.1016/S0002-9343(97)00014-4

Identifiers

DOI

1 reference

30 July 2017

1 reference